Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Classical hematology 2Gastrointestinal 1

Conditions

Venous Thrombosis 2Venous Thromboembolism 2Pulmonary Embolism 2Gastrointestinal Neoplasms 1

Interventions

Dalteparin 11apixaban 9Enoxaparin 7edoxaban 5Tinzaparin 5Rivaroxaban 4Heparin, Low-Molecular-Weight 4Dabigatran 3bemiparin 2abelacimab 2Warfarin 2Nadroparin 2MAA868 2Fondaparinux 2reviparin 1myotubularin 1isoquercitrin 1certoparin 1atezolizumab 1acarboxyprothrombin 1Ultrasonography, Doppler, Duplex 1Rosuvastatin Calcium 1Phenprocoumon 1Models, Biological 1Medication Therapy Management 1Intermittent Pneumatic Compression Devices 1Imaging, Three-Dimensional 1Hospitals 1Heparin 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Venous Thrombosis × MAA868 × Clear all
NCT05171075 2026-04-17

MAGNOLIA

Anthos Therapeutics, Inc.

Phase 3 Terminated
417 enrolled
Classical hematologyGastrointestinal

Gastrointestinal Neoplasms, Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

NCT05171049 2026-02-23

ASTER

Anthos Therapeutics, Inc.

Phase 3 Terminated
1,150 enrolled
Classical hematology

Pulmonary Embolism, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡